<scp>MUC</scp>1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanismDina Stroopinsky, David Avigan|Journal of Cellular and Molecular Medicine|2018Cited by 15
Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-TGiulia Cheloni, Ioannis S. Vlachos, Eleni Kanata et al.|Blood|2021Cited by 1
Abstract 2257: Activation and clonotypic expansion of the native T cell repertoire identifies durable response to CD19 CAR T cell therapyDimitra Karagkouni, Ioannis S. Vlachos, Brodie Miles et al.|Cancer Research|2023Cited by 1
P-021 Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patientsDimitra Karagkouni, Ioannis S. Vlachos, Giulia Cheloni et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0